Therapy with anti-CD3 antibody teplizumab delayed onset of type 1 diabetes in individuals having close relatives with type 1 diabetes and at least two diabetes-related autoantibodies, according to a study presented at the American Diabetes Association annual meeting and published in the New England Journal of Medicine. All individuals were at least age 8 at the time of the study, with children representing 75% of participants.
Onset of type 1 diabetes delayed in study of anti-CD3 antibody
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.